Anna Lokshin
University of Pittsburgh Cancer Institute, USA
Posters & Accepted Abstracts: J Mol Biomark Diagn
Despite considerable advancements, the development of effective cancer screening tools based on serum biomarker measurements has thus far failed to achieve a meaningful clinical impact. The incremental progress observed over the course of serum biomarker development suggests that further refinements based on novel approaches may yet result in a breakthrough. We will present complementary approaches that could considerable increase power of biomarker-assisted cancer screening including using alternative biofluids, such as urine, analysis of temporal biomarker dynamics prior to diagnosis, and using prospectively collected pre-diagnostic samples for biomarker discovery. Examples of utility of these approaches for development of ovarian and pancreatic cancers screening biomarkers will be presented.
Email: lokshina@pitt.edu
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 